Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cogent Biosciences director Matthew Ros received a stock option grant, not an open‑market trade. He was awarded options for 17,901 shares of common stock at an exercise price of $31.98 per share, expiring on June 9, 2036. The option vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, conditioned on his continued service to the company through that date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ros Matthew
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,901 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,901 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option shares granted: 17,901 shares
Exercise price: $31.98 per share
Total derivative shares after grant: 17,901 shares
+1 more
4 metrics
Option shares granted
17,901 shares
Stock Option (Right to Buy) grant to director Matthew Ros
Exercise price
$31.98 per share
Conversion or exercise price of stock option
Total derivative shares after grant
17,901 shares
Total options held following transaction
Option expiration date
June 9, 2036
Expiry of stock option grant
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Annual Meeting of Stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Annual Meeting of Stockholders financial
"earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders"
vesting financial
"This stock option shall vest in full upon the earlier of the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Cogent Biosciences (COGT) director Matthew Ros report in this Form 4?
Director Matthew Ros reported receiving a stock option grant. The award covers 17,901 shares of Cogent Biosciences common stock as a compensation grant, rather than an open‑market purchase or sale, and is documented as a derivative acquisition on the Form 4.
What is the exercise price of Matthew Ros’s Cogent Biosciences (COGT) stock option?
The exercise price of the stock option granted to Matthew Ros is $31.98 per share. This means he can buy Cogent Biosciences common stock at $31.98 if and when the option becomes vested and he chooses to exercise it.
When do Matthew Ros’s Cogent Biosciences stock options vest according to the filing?
The stock options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Vesting requires that Matthew Ros continue serving Cogent Biosciences through whichever of those dates occurs first.
When do the Cogent Biosciences (COGT) stock options granted to Matthew Ros expire?
The stock options granted to Matthew Ros expire on June 9, 2036. After that expiration date, he would no longer be able to exercise the options to purchase Cogent Biosciences common stock at the stated exercise price.